Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 18050196)

1.

Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.

Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK.

Arthritis Rheum. 2007 Dec;56(12):3995-4004.

2.

A B-cell activating factor receptor (BAFF-R) His159Tyr mutation in Sjögren's Syndrome related lymphoproliferation.

Papageorgiou A, Mavragani CP, Nezos A, Zintzaras E, Quartuccio L, De Vita S, Koutsilieris M, Tzioufas AG, Moutsopoulos HM, Voulgarelis M.

Arthritis Rheumatol. 2015 Jun 19. doi: 10.1002/art.39231. [Epub ahead of print]

PMID:
26097183
3.

Association of BAFF and IL-17A with subphenotypes of primary Sjögren's syndrome.

Deng F, Chen J, Zheng J, Chen Y, Huang R, Yin J, Gao X, Lin Q, Huang C, Gao Y, Yu X, Liu Z.

Int J Rheum Dis. 2015 May 4. doi: 10.1111/1756-185X.12569. [Epub ahead of print]

PMID:
25941062
4.

Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.

Pontarini E, Fabris M, Quartuccio L, Cappeletti M, Calcaterra F, Roberto A, Curcio F, Mavilio D, Della Bella S, De Vita S.

Rheumatology (Oxford). 2015 Mar 3. pii: kev005. [Epub ahead of print]

PMID:
25740829
5.

Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis.

Glaesener S, Quách TD, Onken N, Weller-Heinemann F, Dressler F, Huppertz HI, Thon A, Meyer-Bahlburg A.

Arthritis Rheumatol. 2014 Sep;66(9):2590-600. doi: 10.1002/art.38736.

6.

[Evaluation of dectin-1 and BAFF expression in conjunctival epithelial cells].

Yoshida K, Shoji J, Ishimori A, Nakashima M, Inada N, Sawa M.

Nihon Ganka Gakkai Zasshi. 2014 Apr;118(4):368-77. Japanese.

PMID:
24864436
7.

Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.

De Vita S, Quartuccio L, Salvin S, Picco L, Scott CA, Rupolo M, Fabris M.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):490-4. Epub 2014 May 7.

PMID:
24802131
8.

Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol.

Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, Difronzo NL, Ferrara JL, Giralt S, Madtes DK, Drexler R, White ES, Cooke KR.

Biol Blood Marrow Transplant. 2014 Jun;20(6):858-64. doi: 10.1016/j.bbmt.2014.02.026. Epub 2014 Mar 7.

9.

[Etanercept: does it constitute a risk factor for development of cerebral venous thrombosis?].

Usero-Ruiz M, Díaz-Sánchez M, Moniche-Álvarez F.

Rev Neurol. 2014 Mar 1;58(5):239-40. Spanish.

10.

Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.

Neregård P, Krishnamurthy A, Revu S, Engström M, af Klint E, Catrina AI.

Scand J Rheumatol. 2014;43(2):85-90. doi: 10.3109/03009742.2013.834964. Epub 2013 Dec 9.

PMID:
24313444
11.

Targeting TNF-α suppresses the production of MMP-9 in human salivary gland cells.

Aota K, Azuma M.

Arch Oral Biol. 2013 Dec;58(12):1761-8. doi: 10.1016/j.archoralbio.2013.09.004. Epub 2013 Sep 21.

PMID:
24200302
12.

Anti-tumor necrosis factor α targets protein kinase B/c-Akt-induced resistance of effector cells to suppression in juvenile idiopathic arthritis.

Wehrens EJ, Vastert SJ, Mijnheer G, Meerding J, Klein M, Wulffraat NM, Prakken BJ, van Wijk F.

Arthritis Rheum. 2013 Dec;65(12):3279-84. doi: 10.1002/art.38132.

13.

Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome.

Mumcu G, Biçakçigil M, Yilmaz N, Ozay H, Karaçayli U, Cimilli H, Yavuz S.

Oral Health Prev Dent. 2013;11(3):229-34. doi: 10.3290/j.ohpd.a30172.

PMID:
23878841
14.

MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome.

Maria NI, Brkic Z, Waris M, van Helden-Meeuwsen CG, Heezen K, van de Merwe JP, van Daele PL, Dalm VA, Drexhage HA, Versnel MA.

Ann Rheum Dis. 2014 Jun;73(6):1052-9. doi: 10.1136/annrheumdis-2012-202552. Epub 2013 Jul 6.

15.

Etanercept for the treatment of rheumatoid arthritis.

Lethaby A, Lopez-Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2013 May 31;5:CD004525. doi: 10.1002/14651858.CD004525.pub2. Review.

PMID:
23728649
17.

Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.

De Sanctis S, Marcovecchio ML, Gaspari S, Del Torto M, Mohn A, Chiarelli F, Breda L.

J Rheumatol. 2013 Jun;40(6):943-8. doi: 10.3899/jrheum.121281. Epub 2013 Apr 1.

PMID:
23547210
18.

Brief report: adrenal autoimmunity in primary Sjögren's syndrome.

Mavragani CP, Schini M, Gravani F, Kaltsas G, Moutsopoulos HM.

Arthritis Rheum. 2012 Dec;64(12):4066-71. doi: 10.1002/art.34679.

19.
20.

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

Pollard RP, Abdulahad WH, Vissink A, Hamza N, Burgerhof JG, Meijer JM, Visser A, Huitema MG, Spijkervet FK, Kallenberg CG, Bootsma H, Kroese FG.

Ann Rheum Dis. 2013 Jan;72(1):146-8. doi: 10.1136/annrheumdis-2012-202071. Epub 2012 Jul 31. No abstract available.

PMID:
22851468
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk